Comparison of the effects of rutaecarpine on molecular subtypes of breast cancer

Cokluk E., ÖZMAN Z., Eskiler G. G., Ozkan A. D., Sekeroglu M. R.

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, vol.17, no.4, pp.988-993, 2021 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 17 Issue: 4
  • Publication Date: 2021
  • Doi Number: 10.4103/jcrt.jcrt_1182_20
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, CINAHL, EMBASE, MEDLINE, Veterinary Science Database
  • Page Numbers: pp.988-993
  • Keywords: Apoptosis, breast cancer, rutaecarpine, subtype, EVODIAMINE, CYCLOOXYGENASE-2, EXPRESSION, COX-2, ACCUMULATION, INHIBITORS
  • Bezmialem Vakıf University Affiliated: Yes


Objective: Natural compounds have gained considerable attention in recent years due to disadvantages and properties of current chemotherapy drugs in cancer therapy. In addition, the impact of these compounds is specific for each type and/or subtypes of cancer due to different treatment response. Rutaecarpine, an alkaloid obtained from Evodia Rutaecarpa Chinese herb, has anticancer activity by inhibiting topoisomerase and/or cyclo-oxygenase-2 levels. However, the effectiveness of rutaecarpine has not been well known in breast cancer in terms of subtype. Therefore, we investigated the potential therapeutic effects of rutaecarpine on two different subtypes of breast cancer cells.